ABVC BioPharma, Inc.
ABVC
$1.05
-$0.035-3.24%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 2.20K | 15.90K | 6.10K | 128.30K | 589.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.20K | 15.90K | 6.10K | 128.30K | 589.00K |
| Cost of Revenue | 139.20K | 29.60K | 73.00K | 60.20K | 265.40K |
| Gross Profit | -137.00K | -13.70K | -66.90K | 68.00K | 323.60K |
| SG&A Expenses | 1.75M | 2.00M | 1.61M | 1.64M | 1.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.96M | 2.17M | 2.20M | 2.03M | 3.72M |
| Operating Income | -1.96M | -2.15M | -2.19M | -1.91M | -3.13M |
| Income Before Tax | -3.15M | -3.37M | -2.23M | -1.90M | -3.54M |
| Income Tax Expenses | 175.30K | -1.00K | 81.70K | -- | 962.90K |
| Earnings from Continuing Operations | -3.33M | -3.37M | -2.32M | -1.90M | -4.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 218.80K | 50.60K | 51.70K | 73.50K | -363.00K |
| Net Income | -3.11M | -3.32M | -2.26M | -1.82M | -4.86M |
| EBIT | -1.96M | -2.15M | -2.19M | -1.91M | -3.13M |
| EBITDA | -1.95M | -2.15M | -2.19M | -1.90M | -3.13M |
| EPS Basic | -0.47 | -0.82 | -0.68 | -0.55 | -1.47 |
| Normalized Basic EPS | -0.24 | -0.51 | -0.41 | -0.34 | -0.76 |
| EPS Diluted | -0.47 | -0.82 | -0.68 | -0.60 | -1.47 |
| Normalized Diluted EPS | -0.24 | -0.51 | -0.41 | -0.34 | -0.76 |
| Average Basic Shares Outstanding | 6.68M | 4.06M | 3.31M | 3.31M | 3.31M |
| Average Diluted Shares Outstanding | 6.68M | 4.06M | 3.31M | 3.31M | 3.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
